Theragnostics reports Phase I data for prostate cancer imaging agent

Theragnostics Ltd. (Bracknell, U.K.) said PET/CT imaging agent 68Ga-THP-PSMA did not lead to any adverse events in a Phase I trial in 14 patients with biopsy proven adenocarcinoma of the prostate. The trial compared the candidate to a standard-of-care (SOC) imaging agent in treatment-naïve patients scheduled for prostatectomy and in patients with metastatic disease. Theragnostics also said that uptake seen in the prostate on 68Ga-THP-PSMA PET/CT imaging correlated with histopathologic prostate-specific membrane antigen (PSMA; FOLH1; GCPII) expression seen on pathology finding following prostatectomy. The trial was sponsored by the Peter MacCallum Cancer Centre. Data were published in The Journal of Nuclear Medicine...